Category Archives: Jim’s Corner

Protection against Seasonal Flu

Today, BIO offered seasonal flu vaccines to all employees, many of whom joined me in getting one.  While getting vaccinated against seasonal flu is important, it will not protect us from H1N1 flu so we were advised to get vaccinated against that once it is available. BIO member companies have played a major role in the development and distribution of both the seasonal influenza vaccination and the H1N1 vaccination.  Five BIO member companies are at Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Biotech Advances in South Dakota

Biotech Advances in South Dakota

Last week I made my first visit to our South Dakota affiliate. The South Dakota Biotech Association, formed in 2006, held its fourth annual conference on Thursday, September 17th. I began my tour on Wednesday at Hematech, Inc.   The company, headquartered in Sioux Falls, is developing cattle that can efficiently produce human antibodies.  The genetically altered cattle will be used for the production of large quantities of polyclonal antibodies.  These antibodies are expected to help Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Touring Local Biotech Companies with Former Governor Dean

Touring Local Biotech Companies with Former Governor Dean

Last week I spent a fascinating day with former Vermont Governor Howard Dean and three Members of the Maryland Congressional delegation.  First, along with local Congressman Roscoe Bartlett (R, MD-6), we visited MedImunne’s brand new biologic manufacturing facility in Frederick. The half billion dollar facility is nearly complete and will employ 350 people manufacturing the company’s monoclonal antibody, Synagis. This product helps prevent lower respiratory disease from a common virus which in vulnerable children, particularly Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Jim Greenwood guest appearance on CNBC’s “Squawk Box” during this morning’s “Health Care Summit” special

BIO President and CEO Jim Greenwood joined former HHS Secretary Tommy Thompson and former FDA Deputy Commissioner Scott Gottlieb to discuss biosimilars and the importance of preserving innovation as the nation moves to reform our health care system.

Jim's Corner  |  Leave a comment  |  Email This Post

Clearing Another Hurdle on the Pathway to Biosimilars

The House Energy and Commerce Committee, by a vote of 47 to 11, overwhelmingly adopted an amendment creating a regulatory pathway for biosimilars that will provide 12 years of data exclusivity for innovative biologics. The strong bipartisan support for this amendment to the America’s Affordable Health Choices Act marks the second win this month for a fair and balanced approach to biosimilars market entry. This vote was a clear victory for patients. The ALS Association Read More >

Jim's Corner  |  Leave a comment  |  Email This Post